All Outputs (3)

Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions (2013)
Journal Article
Pacelli, A., Greenman, J., Cawthorne, C., & Smith, G. (2014). Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions. Journal of Labelled Compounds and Radiopharmaceuticals, 57(4), 317-322. https://doi.org/10.1002/jlcr.3160

The role of cyclooxygenase (COX)-2 as a driving force in early tumourigenesis and the current interest in the combination of COX-2 inhibitors with standard therapy in clinical trials creates an urgent need to establish clinically relevant diagnostic... Read More about Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions.

A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers (2013)
Journal Article
Simpson, K. L., Cawthorne, C., Zhou, C., Hodgkinson, C. L., Walker, M. J., Trapani, F., Kadirvel, M., Brown, G., Dawson, M. J., MacFarlane, M., Williams, K. J., Whetton, A. D., & Dive, C. (2013). A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers. Cell Death and Disease, 4(5), e613-e613. https://doi.org/10.1038/cddis.2013.137

Novel anticancer drugs targeting key apoptosis regulators have been developed and are undergoing clinical trials. Pharmacodynamic biomarkers to define the optimum dose of drug that provokes tumor apoptosis are in demand; acquisition of longitudinal t... Read More about A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers.

[18F]-FLT Positron Emission Tomography Can Be Used to Image the Response of Sensitive Tumors to PI3-Kinase Inhibition with the Novel Agent GDC-0941 (2013)
Journal Article
Cawthorne, C., Burrows, N., Gieling, R. G., Morrow, C. J., Forster, D., Gregory, J., Radigois, M., Smigova, A., Babur, M., Simpson, K., Hodgkinson, C., Brown, G., McMahon, A., Dive, C., Hiscock, D., Wilson, I., & Williams, K. J. (2013). [18F]-FLT Positron Emission Tomography Can Be Used to Image the Response of Sensitive Tumors to PI3-Kinase Inhibition with the Novel Agent GDC-0941. Molecular Cancer Therapeutics, 12(5), 819-828. https://doi.org/10.1158/1535-7163.mct-12-0905

The phosphoinositide 3-kinase (PI3K) pathway is deregulated in a range of cancers, and several targeted inhibitors are entering the clinic. This study aimed to investigate whether the positron emission tomography tracer 3′-deoxy-3′-[ 18 F]fluorothymi... Read More about [18F]-FLT Positron Emission Tomography Can Be Used to Image the Response of Sensitive Tumors to PI3-Kinase Inhibition with the Novel Agent GDC-0941.